NASDAQ:ECOR - Nasdaq - US28531P2020 - Common Stock - Currency: USD
5.4
+0.45 (+9.09%)
The current stock price of ECOR is 5.4 USD. In the past month the price decreased by -10.3%. In the past year, price decreased by -22.86%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.2 | 233.79B | ||
ISRG | INTUITIVE SURGICAL INC | 73.77 | 202.01B | ||
BSX | BOSTON SCIENTIFIC CORP | 39.27 | 156.84B | ||
SYK | STRYKER CORP | 31.46 | 150.47B | ||
MDT | MEDTRONIC PLC | 16.19 | 110.86B | ||
BDX | BECTON DICKINSON AND CO | 12.45 | 50.37B | ||
EW | EDWARDS LIFESCIENCES CORP | 30 | 45.86B | ||
IDXX | IDEXX LABORATORIES INC | 45.45 | 41.99B | ||
RMD | RESMED INC | 27.72 | 36.91B | ||
DXCM | DEXCOM INC | 51.81 | 33.52B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.9 | 33.48B | ||
STE | STERIS PLC | 26.94 | 24.72B |
electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 73 full-time employees. The company went IPO on 2018-06-22. The company provides a non-invasive vagus nerve stimulation (nVNS) technology platform. The Company’s product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headache, and handheld, personal use consumer products utilizing nVNS technology to promote general wellness and human performance. Its products include gammaCore, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com. TAC-STIM is a portable device that is designed specifically for use by the Military. The company stimulates the vagus nerve, only needs a few minutes to administer, and has long-lasting benefits.
ELECTROCORE INC
200 Forge Way, Suite 205
Rockaway NEW JERSEY 07866 US
CEO: Daniel S. Goldberger
Employees: 73
Phone: 19732900097
The current stock price of ECOR is 5.4 USD. The price increased by 9.09% in the last trading session.
The exchange symbol of ELECTROCORE INC is ECOR and it is listed on the Nasdaq exchange.
ECOR stock is listed on the Nasdaq exchange.
11 analysts have analysed ECOR and the average price target is 25.7 USD. This implies a price increase of 376% is expected in the next year compared to the current price of 5.4. Check the ELECTROCORE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ELECTROCORE INC (ECOR) has a market capitalization of 38.83M USD. This makes ECOR a Nano Cap stock.
ELECTROCORE INC (ECOR) currently has 73 employees.
ELECTROCORE INC (ECOR) has a support level at 4.64 and a resistance level at 5.41. Check the full technical report for a detailed analysis of ECOR support and resistance levels.
The Revenue of ELECTROCORE INC (ECOR) is expected to grow by 24.6% in the next year. Check the estimates tab for more information on the ECOR EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ECOR does not pay a dividend.
ELECTROCORE INC (ECOR) will report earnings on 2025-08-05, after the market close.
ELECTROCORE INC (ECOR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.56).
The outstanding short interest for ELECTROCORE INC (ECOR) is 5.14% of its float. Check the ownership tab for more information on the ECOR short interest.
ChartMill assigns a fundamental rating of 3 / 10 to ECOR. While ECOR seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months ECOR reported a non-GAAP Earnings per Share(EPS) of -1.56. The EPS increased by 45.07% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -58.06% | ||
ROE | -157.56% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 84% to ECOR. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 22.69% and a revenue growth 24.6% for ECOR